Capital stacks and blueprints
Documented real-world structure
Volume guarantee platform
A documented structure: capital layers, funding and repayment flows, risk allocation and limitations.
- Last reviewed
- Related chapter
- Philanthropy as Amplifier
Label: Documented real-world structure. Source: MedAccess, 2025 Annual Review and Accounts (case 3).
Problem addressed. A manufacturer will not supply a health product at a lower price without a volume commitment; a procurer cannot commit to volume without a price.
Layers and roles
| Layer | Capital or commitment | Provider | Role |
|---|---|---|---|
| Guarantee capital | USD 170 million | British International Investment | Stands behind the guarantees; the balance sheet. |
| Counter-guarantee | Up to EUR 52 million, covering up to 30 percent of losses on eligible African guarantees | European Investment Bank (2025) | Shares the balance-sheet risk. |
| Operating grants | Amounts not public | FCDO, Gates Foundation, Wellcome (since 2021) | Fund scoping, negotiation, execution, and monitoring of agreements. |
| Fees | Not public | Counterparties | Cover partnership costs. |
Funding flows. No capital flows to the manufacturer or procurer at signing. MedAccess signs a volume guarantee: if purchases fall below an agreed floor, MedAccess pays the manufacturer the shortfall.
Repayment flows. None in the conventional sense. If volumes are met, the guarantee expires unused. Fees cover operating costs; surpluses are reinvested.
Risk allocation. MedAccess (backed by BII, and partly by EIB) carries volume risk. Manufacturer is protected against the downside of a lower price. Procurer gets the lower price without a volume commitment.
What the philanthropic contribution enables. The grants fund the work of structuring. Without them, the balance sheet would sit idle. The Gates Foundation, Wellcome, and FCDO are paying for the expertise that turns capital into agreements.
Governance and accountability. Annual accounts; disclosure statement; impact case studies; an impact method that projects "additional" outcomes against a no-intervention scenario, with MedAccess stating it claims contribution rather than credit.
Reported scale (end 2025). 18 transactions; USD 872 million in sales enabled; USD 228 million in procurer savings; net exposure around USD 128 million; guarantee liability around USD 1.6 million. No calls or realised losses reported.
Conditions under which the structure may not work. A demand shock that triggers multiple calls at once. A manufacturer that uses the guaranteed floor to under-invest in distribution. A procurer that would have bought at the lower price anyway. The model has not yet been stress-tested by a large call.
Sources
Educational material, not investment, legal or tax advice. Reported figures and review dates reflect the cited sources and editorial review; they are not live data.
